DSIP (Delta-Sleep-Inducing-Peptide): The Unsolved Riddle of Sleep Research

Few molecules in peptide research are so strangely famous and at the same time so poorly understood as DSIP. The Delta-Sleep-Inducing-Peptide was isolated almost half a century ago, carries a name that promises a clear function, and yet remains one of the most stubborn riddles in neuroendocrinology. A 2006 review in the Journal of Neurochemistry put it plainly in its title: DSIP is "a still unresolved riddle" (PMID 16539679). This article shows what is actually known, what is not, the real findings per study, the very short pharmacokinetics, and the regulatory developments of 2026. It is written purely for laboratory and educational purposes and is not a therapeutic recommendation.

What DSIP Is and Where It Comes From

DSIP is a small nonapeptide: just nine amino acids, sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, with the molecular formula C35H48N10O15 and a molecular mass of about 848.8 g/mol (PubChem CID 68816, CAS 62568-57-4). Its origin story explains part of the fascination. In the mid-1970s, Swiss researchers around Schoenenberger and Monnier electrically induced a sleep-like state in rabbits, drew blood, and searched for a circulating factor that could transfer that state to a recipient animal. The peptide isolated from the blood of these sleeping rabbits was named after the delta sleep (deep sleep) it appeared to promote. That is the entire basis of the name: a behavioral observation, not a defined receptor and not a signaling pathway.

The Honest Mechanism: Almost 50 Years, No Confirmed Receptor

This is the part most marketing copy skips. Despite decades of work, no DSIP gene, no dedicated DSIP receptor, and no fully characterized signaling pathway have been isolated to this day. The review by Kovalzon and Strekalova (2006) notes that "the connection between DSIP and sleep has never been further characterized, in part because of the failure to isolate the DSIP gene, protein, and possible associated receptor", and calls the sleep-factor hypothesis "extremely weakly supported" (PMID 16539679). The authors even consider the possibility that a different, DSIP-like peptide, rather than DSIP itself, may be responsible for some of the sleep effects reported in older animal experiments.

This is an unusually candid verdict from inside the field, and it should frame everything that follows. DSIP is not a molecule with a clean, accepted mechanism. It is a molecule with a name, a handful of intriguing studies, and a large question mark where the receptor should be.

Three Research Strands

Across the scattered literature, DSIP research clusters around three loose strands. None is settled, yet each rests on at least one real study.

1. Sleep

The most cited human study is small. Schneider-Helmert and Schoenenberger gave six middle-aged people with chronic insomnia a single intravenous dose of synthetic DSIP of 25 nmol/kg (about 21 mcg/kg). They reported longer sleep duration, better subjective sleep quality, fewer interruptions, and somewhat more REM sleep, with effects lasting up to six hours and no daytime drowsiness or sedation. They described a "normalizing influence on human sleep regulation" rather than a numbing effect (PMID 7028502).

2. HPA Axis, Stress, and Substance P

A separate rat strand looked at stress physiology rather than sleep. Salieva and colleagues found that a single dose of DSIP given before a stressor increased substance P content in the hypothalamus and raised stress resistance; at 60 nmol/kg (intraperitoneal) it markedly reduced two classic stress markers, adrenal hypertrophy and thymus involution, with the lower dose showing the strongest effect (PMID 1382246). Importantly, this study measured organ-related stress markers and hypothalamic substance P, not blood ACTH or cortisol directly. The broader claim of HPA-axis dampening is therefore an inference from these endpoints, not a direct hormone measurement.

3. Antioxidant and Geroprotective Effects

The third strand is biochemical and almost exclusively in rats. Under cold stress, DSIP at 12 mcg per 100 g of body weight increased the activity of superoxide dismutase, catalase, and glutathione peroxidase and restored the pro-oxidant/antioxidant balance disrupted by cold stress (PMID 11421812). A later geroprotection study treated aging rats (2 to 24 months) with 10 mcg per 100 g subcutaneously on five consecutive days per month and reported suppressed lipid peroxidation along with increased SOD, catalase, and ceruloplasmin activity, with the strongest effect in older animals (PMID 21809625). These are mechanistically interesting findings in rodents and do not demonstrate any anti-aging effect in humans.

Pharmacokinetics: Gone in Minutes

One practical finding runs through all the strands: DSIP disappears from circulation extraordinarily fast. A clearance study using an enzyme immunoassay measured intravenous half-lives of about 4.0 minutes in dogs, 2.9 minutes in monkeys, and 2.0 minutes in rats, with a metabolic clearance rate of around 30.7 ml/kg/min in dogs (PMID 6379493). A half-life measured in the single-digit minute range makes the multi-hour sleep effects reported in the human study (PMID 7028502) all the more puzzling, and is another reason the mechanism remains contested. It also means that the parent peptide does not linger in the body, whatever downstream effects it may trigger.

The 2026 Regulatory Moment

DSIP is having a regulatory moment in the US right now, and it is worth getting the facts exactly right, because the nuance matters. DSIP is not an approved drug and not patented. Under the name Emideltide (both as acetate and as free base), it was on the FDA 503A Category 2 list, the bin for substances with significant safety concerns. In the updated 503A document of 15 April 2026, Emideltide/DSIP was removed from Category 2 effective 22 April 2026, as part of a group of twelve peptides whose petitioners withdrew their nominations before review.

The crucial caveat: removal from Category 2 is not, in itself, a compounding clearance. It does not place the substance under any tolerance policy. The FDA's Pharmacy Compounding Advisory Committee (PCAC) is scheduled to review DSIP together with Epitalon and Semax on 24 July 2026. Only a positive recommendation and subsequent addition to the 503A bulks list would open a clear compounding pathway. We cover the bigger picture in our posts on the Category 2 removal and on the PCAC hearing in July 2026 from an EU perspective. None of this changes the status in the EU, where DSIP is supplied exclusively for research purposes.

What the Evidence Shows and What It Does Not

It helps to separate the signal from the hope. The evidence shows that synthetic DSIP has been administered in published studies in humans and animals without reports of severe acute toxicity at the doses used, that a small human study reported improved subjective sleep scores, that rodent work points to activation of antioxidant enzymes and a reduction in stress markers, and that the peptide disappears from the blood within minutes. The evidence shows no defined receptor or signaling pathway, no large or controlled human sleep studies, no proven anti-aging or stress benefit in humans, and no approved therapeutic use anywhere.

Storage and Reconstitution

DSIP is supplied as a lyophilized (freeze-dried) powder. In research, lyophilized peptides of this kind are usually stored cool and dark and reconstituted only when needed with sterile bacteriostatic water; the reconstituted solution is then refrigerated and used within a limited window, since small peptides in solution are less stable than the dry powder. These are general handling notes for the laboratory context, not dosing or use instructions.

Bacteriostatic Wateraccessories

USP-grade sterile water with 0.9% benzyl alcohol - the standard solvent for reconstituting lyophilized peptides. Essential accessory for any peptide research. Each vial is sealed and ready to use.

Where DSIP Sits in the Catalog

Because its defining, name-giving role is sleep and stress regulation via the central nervous system, we place DSIP in the Cognitive category, alongside other neuroactive research peptides. It remains, in the words of the literature itself, a riddle: a peptide named after a function it could never fully demonstrate, stepping back into the regulatory spotlight in 2026.

DSIPcognitive

DSIP (Delta Sleep-Inducing Peptide), a nonapeptide isolated in 1977. Research material for sleep, HPA-axis, and stress regulation. Research-grade lyophilized powder, laboratory use only.

Selankcognitive

Synthetic tuftsin analog with anxiolytic, nootropic, and immunomodulatory properties. Developed at the Russian Academy of Sciences.

Semaxcognitive

Brain-boosting nootropic peptide derived from ACTH. Increases BDNF (brain-derived neurotrophic factor), enhances focus, memory, and mental clarity. Widely used in Russian clinical practice for cognitive enhancement.

Epitalonlongevity

Tetrapeptide (Ala-Glu-Asp-Gly) that activates telomerase, the enzyme responsible for maintaining telomere length. One of the most studied peptides in longevity research, developed by Prof. Khavinson at the St. Petersburg Institute of Bioregulation.

Frequently Asked Questions